Table 1.
Clinico-pathological characteristics of patients
| No. (%) |
|||
|---|---|---|---|
| Total | Benign (N=21) | High grade serous cancer (N=9) | |
| Median age (range) | 54.5 (19–82) | 51 (19–82) | 65 (48–72) |
| Menopausal status | |||
| Pre | 10 (33.3%) | 9 (42.9%) | 1 (11.1%) |
| Post | 20 (66.7%) | 12 (57.1%) | 8 (88.9%) |
| Mutation status | |||
| None | 18 (60.0%) | 12 (57.1%) | 6 (66.7%) |
| BRCA1 | 6 (20.0%) | 3 (14.3%) | 3 (33.3%) |
| BRCA2 | 6 (20.0%) | 6 (28.6%) | |
| Histology | |||
| No neoplasm | 12 (40%) | 12 (57.1%) | |
| Benign neoplasm* | 9 (30%) | 9 (42.9%) | |
| High grade serous cancer | 9 (30%) | 9 (100%) | |
| Stage | |||
| III | 8 (88.9%) | ||
| IV | 1 (11.1%) | ||
| Prior cancer diagnosis | |||
| No | 29 (96.7%) | 21 (100%) | 8 (88.9%) |
| Yes | 1 (3.3%) | 1 (11.1%) | |
| Prior chemotherapy | |||
| No | 28 (93.3%) | 21 (100%) | 7 (77.8%) |
| Yes | 2 (6.7%)† | 2 (22.2%)† | |
*
Benign neoplasms included serous cystadenoma, mucinous cystadenoma, serous cystadenofibroma, endometriosis, salpingitis, fibroma, cellular angiofibroma, and struma ovarii
†
Received neoadjuvant chemotherapy for ovarian cancer